日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

利用患者来源的异种移植模型建立胆道癌精准肿瘤学模型

Timothy P DiPeri, Kurt W Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N Kwong, Michael Kahle, Hop S Tran Cao, Ching-Wei Tzeng, Thuy Vu, Sunhee Kim, Fei Su, Maria Gabriela Raso, Yasmeen Rizvi, Ming Zhao, Huamin Wang, Sunyoung S Lee, Timothy A Yap, Jordi Rodon, Milind Javle, Fun

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Adavosertib 增强 Trastuzumab Deruxtecan 在 HER2 表达癌症中的抗肿瘤活性

Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q Rizvi, Xiaofeng Zheng, Bailiang Wang, Bryce P Kirby, Kathleen Kong, Michael Kahle, Timothy A Yap, Ecaterina E Dumbrava, Jaffer A Ajani, Siqing Fu, Khandan Keyomarsi, Funda Meric-Bernstam

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

表观遗传上调 TROP2 和 SLFN11 可增强 TROP2 抗体药物偶联物 sacitizumab govitecan 的治疗效果

Ming Zhao, Timothy P DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E Dumbrava, Senthil Damodaran, Funda Meric-Bernstam

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

不可逆成纤维细胞生长因子受体抑制剂富巴替尼在FGFR改变的乳腺癌中的疗效

Turcin Saridogan ,Argun Akcakanat ,Ming Zhao ,Kurt W Evans ,Erkan Yuca ,Stephen Scott ,Bryce P Kirby ,Xiaofeng Zheng ,Min Jin Ha ,Huiqin Chen ,Patrick K S Ng ,Timothy P DiPeri ,Gordon B Mills ,Jordi Rodon Ahnert ,Senthil Damodaran ,Funda Meric-Bernstam